HIV感染者甲型肝炎疫苗免疫应答研究
该回顾性横断面研究评估了HIV阳性患者完成甲肝疫苗全程接种后的血清转化率及相关影响因素。结果显示80.2%的患者产生抗HAV抗体,单苗组81.5%、甲乙肝联合疫苗组79.2%。多因素分析显示疫苗至血清学检测间隔超过5年与血清转化率下降显著相关。
要点
- HIV阳性患者接种甲肝疫苗后总体血清转化率为80.2%。
- 单苗组中较高CD4计数、较高CD4/CD8比值与更好应答相关。
- 疫苗至血清学检测间隔超过5年与血清转化率下降显著相关。
核心结论
- HIV阳性患者对甲肝疫苗的应答受损。
- 至少30岁以上的HIV患者应在接种甲肝疫苗后检测血清转化。
- 甲肝抗体滴度可能快速下降,建议随访期间进行血清学监测,可能在两年内。
- 疫苗类型对疫苗应答无影响。
研究设计与样本
- 回顾性横断面研究。
- 纳入完成甲肝疫苗全程接种的HIV阳性患者,检测HAV抗体。
- 评估CD4细胞计数、CD4/CD8比值、血浆病毒载量、疫苗类型及接种时抗逆转录病毒治疗等因素的影响。
主要发现
- 接种后80.2%的患者产生抗HAV抗体。
- 单苗组血清转化率为81.5%,甲乙肝联合疫苗组为79.2%。
- 单苗组中较高CD4细胞计数、较高CD4/CD8比值及较短疫苗至血清学检测间隔与更好应答显著相关。
- 联合疫苗组中较年轻年龄和女性性别与更好疫苗应答显著相关。
- 多因素逻辑回归分析显示疫苗至血清学检测间隔超过5年相比少于1年与HAV疫苗血清转化下降显著相关。
临床怎么用
- HIV患者接种甲肝疫苗后应检测血清转化,至少30岁以上者。
- 随访期间建议进行血清学监测,可能在两年内。
- 疫苗类型不影响应答,选择疫苗时无需考虑此因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to evaluate the impact of various factors that may influence the immunologic response to hepatitis A mono-vaccine or hepatitis A/B co-vaccine (Twinrix®) in HIV-infected patients. DESIGN: Retrospective cross-sectional study. METHODS: HIV positive patients with a full course of hepatitis A vaccine were tested for HAV antibodies. The seroconversion rates were determined, and the influence of several factors including CD4 cell counts, CD4/CD8 ratio, plasma viral load, type of vaccine, and antiretroviral therapy at the time of vaccine, was evaluated. RESULTS: After vaccination, 80.2% of the patients developed anti-HAV antibodies, 81.5% in the mono-vaccine group and 79.2% in the hepatitis A/B co-vaccine group. In the mono-vaccine group, factors significantly associated with a better response to the vaccine were higher CD4 cell count, higher CD4/CD8 ratio, and shorter time interval from vaccine to serological control. In patients who received the hepatitis A/B co-vaccine, younger age and female sex were significantly associated with better vaccine response. Multivariable logistic regression analysis revealed time interval from vaccine to serological control of more than 5 years vs. less than 1 year to be significantly associated with decrease of seroconversion after HAV vaccine. CONCLUSIONS: The response to hepatitis A vaccine is impaired in HIV positive patients. HIV patients, at least those older than 30, should be tested for seroconversion after receiving the hepatitis A vaccine. As hepatitis A titers may rapidly decline, control serology during follow-up should be proposed, possibly within two years. However, vaccine type does not play a role in vaccine response.
引用
- Fritzsche C, Bergmann L, Loebermann M, et al. Immune response to hepatitis A vaccine in patients with HIV. Vaccine. 2019. PMID: 30890384. doi:10.1016/j.vaccine.2019.02.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。